Sign in

Research summary ·

Efficacy and Safety of Dupilumab in Eosinophilic Esophagitis: A Systematic Review and Meta-Analysis.

Written based on 1 research study on PubMed, searched on 15 Nov 2026.

What was studied

This review pooled studies of dupilumab in people with eosinophilic esophagitis, or EoE. EoE is a long-term immune disease of the food pipe. Dupilumab is an antibody drug that blocks a part used by IL-4 and IL-13. The team searched medical databases up to June 30, 2025. They looked at trials, group studies, and single case reports. In all, 760 people, children and adults, were included.

What they found

Most people began dupilumab after other care had not worked or was not tolerated. That earlier care was acid drugs, swallowed steroids, or diet changes. In the trials, the food pipe lining calmed down more often with dupilumab. This was judged by counting a type of immune cell under a microscope. Placebo, a dummy drug, led to this far less often. Group studies showed similar results, and children seemed to respond very well. Pooled results showed both tissue gains and symptom gains with dupilumab.

What it means for patients

The authors see dupilumab as a hopeful choice for treating EoE. They say this is so for people whose acid drugs did not help enough. This includes people who cannot keep up a strict diet. The abstract also says side effects were looked at, but gives no details.

Why it is not certain yet

The review mixed trials with group studies and single case reports. The authors say it is not yet known who will respond. They say it is unclear if results last beyond 1 year. Dupilumab also still needs to be compared with other treatments. A review can only be as good as the studies in it.

Source

Efficacy and Safety of Dupilumab in Eosinophilic Esophagitis: A Systematic Review and Meta-Analysis.

PubMed · PMID 42455743

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Eosinophilic oesophagitis publications
Efficacy and Safety of Dupilumab in Eosinophilic Esophagitis: A Systematic Review and Meta-Analysis. · Eosinophilic oesophagitis news explained – Frontlight Research